Dolutegravir agreement continue collaboration between British company and Unitaid-launched treatment access organization With a high barrier to drug-resistance, low production costs, low dosing and a potential for pediatric use, the new HIV drug dolutegravir, approved by the U.S. Food and Drug Administration in August, and for use among adults and adolescents by the European Medicines […]